Physician profile
David E Obudzinski
NPI 1265418867
$2,083.42
in general payments reported to CMS, 2019-2025
21 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $136 · 2021: $489 · 2022: $474 · 2023: $160 · 2024: $296 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644 · Education: $8.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.50 |
| Education | $8.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $487.74 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $291.79 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $227.95 | 2022-2024 | Azstarys |
| Tris Pharma INC | $193.95 | 2019-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $136.95 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Sanofi Pasteur INC. | $130.22 | 2020-2023 | |
| Adlon Therapeutics L.P. | $123.35 | 2020-2021 | |
| Cranial Technologies, INC | $81.87 | 2019-2022 | |
| Alk-Abello, INC | $72.11 | 2023-2025 | Grastek, Ragwitek, Odactra |
| Merck Sharp & Dohme LLC | $63.01 | 2021-2023 | Proquad, Gardasil 9, Vaxneuvance |
| Collegium Pharmaceutical, INC. | $42.76 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $41.38 | 2019-2025 | Elaprase |
| Sobi, INC | $39.84 | 2019 | |
| Neos Therapeutics, Lp | $28.38 | 2019 | |
| Phadia US INC. | $24.54 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.10 | 2019 | |
| Pfizer INC. | $22.00 | 2019 | |
| Mirum Pharmaceuticals, INC. | $16.16 | 2024 | Cholbam |
| Vertical Pharmaceuticals, LLC | $14.88 | 2025 | Relexxii |
| Kaleo, INC. | $11.88 | 2019 | |
| Travere Therapeutics, INC. | $8.56 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Obudzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.